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Abstract
Purpose Patient-reported outcome measures, including satisfaction with treatment decisions, provide important information 
in addition to clinical outcomes, survival and decision-making in lung cancer surgery. We investigated associations between 
preoperative clinical and socio-demographic factors and patient-reported satisfaction 6 weeks after radical treatment for 
early-stage non-small cell lung cancer (NSCLC).
Methods We conducted a sub-group analysis of the prospective observational longitudinal study of 225 participants in two 
treatment groups—surgical (VATS) and radiotherapy (SABR). The Patient Satisfaction Questionnaire-18 (PSQ-18) was used 
to measure patient satisfaction 6 weeks after treatment. Clinical variables, Index of Multiple Deprivation decile and Decision 
self-efficacy scores were used in regression analysis. Variables with a p level < 0.1 were used as independent predictors in 
generalised linear logistic regression analyses.
Results As expected, the two groups differed in pre-treatment clinical features. The SABR group experienced more grade 
1–2 complications than the VATS group. No differences were found between the groups in any subscale of the PSQ-18 ques-
tionnaire. Patients experiencing complications or living in more deprived areas were more satisfied with care. Properative 
factors independently associated with patient satisfaction were the efficacy in decision-making and age.
Conclusion We showed that efficacy in treatment decision-making and age was the sole predictor of patient satisfaction 
with their care after radical treatment for early-stage NSCLC. Patients from more deprived areas and patients who suffered 
complications reported greater subsequent satisfaction. Involving patients in their care may improve satisfaction after treat-
ment for early-stage NSCLC.
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Abbreviations
MIS  Minimally invasive surgery
NICE  National Institute for Clinical Excellence
NIHR  National Institute for Health Research
NSCLC  Non-small cell lung cancer
PROs  Patient-reported outcomes
PROMs  Patient-reported outcome measures
SABR  Stereotactic ablative radiotherapy
VATS  Video-assisted thoracoscopic surgery
Introduction
Lung cancer is associated with high morbidity and mortality. 
In addition, significant comorbidities often markedly reduce 
the patient’s baseline performance status. The high preva-
lence and significant symptomatic burden of lung cancer 
on patients is befitting to patient satisfaction as a surgical 
outcome measure.
UK National Institute for Clinical Excellence (NICE) 
guidelines recommend that early-stage non-small cell 
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lung cancer is treated using video-assisted thoracoscopic 
surgery (VATS) for fit patients, and stereotactic ablation 
radiotherapy (SABR) for patients for whom VATS is not 
appropriate (NICE 2019).
Patient-reported outcome measures (PROMS) provide 
information additional to long-term survival, risk–benefit 
decision-making and surgical outcomes in lung cancer sur-
gery. Patient satisfaction is one of many important PROMS 
and is vital to assess the quality of treatment (Chow et al. 
2009). Patient satisfaction with treatment is a key quality 
indicator for lung cancer care (Brunelli and Rocco 2007) 
as it reflects a patient’s perception of the quality of care 
received. Although clinical indicators improve with sur-
gery, it is likely that patient-reported experience of care 
gets worse after treatment due to the prevalence and impact 
of symptoms that result from different treatments. As a 
consequence, measuring patient perception of satisfaction 
with the process of care is essential to delivering effective 
practice and enhancing patient-centred management.
There are no specific lung cancer questionnaires to 
assess patient satisfaction with care. Satisfaction is an 
abstract and multi-dimensional concept which is difficult 
to directly observe or measure; therefore, it should be eval-
uated using a variety of multi-item scales (Avery et al. 
2006). Measuring patient satisfaction requires validated 
tools, of which there are multiple options. Nevertheless, 
the consistent association of socio-economic inequality 
in relation to lung cancer incidence and mortality (Mack-
enback et al. 2004) is questioning if health disparity and 
challenges in access to lung cancer care can affect patient 
satisfaction after treatment.
The aim of this study is to investigate whether any spe-
cific preoperative factors, either clinical, demographic or 
patient-reported, were related to patient satisfaction with 
care at 6 weeks after surgical or stereotactic radiotherapy 
treatment of lung cancer.
We hypothesized that there is an association between 
patient decision-making efficacy for lung cancer treatment 
and their post-treatment satisfaction.
Materials and methods
This study is a sub-analysis of the Lilac study, a prospec-
tive observational longitudinal study with repeated patient-
reported outcome measures at baseline, 6 weeks and 3, 
6 and 12 months after radical treatments for early-stage 
(stages I–II) non-small-cell lung cancer (NSCLC). The 
study cohort comprised consecutive patients undergoing 
VATS anatomical lung resection or SABR for early-stage 
NSCLC at a single UK centre during a period of 12 months. 
All participants signed a written consent form and the study 
received ethical approval from The National Research Ethics 
Service Yorkshire and the Humber-Leeds East Committee 
(REC Ref: 16/YH/0407). This study has been registered in 
the Clinical Trial database (ClinicalTrials.gov Identifier: 
NCT02882750).
Treatment groups
The study population were patients with early-stage lung 
cancer treated with either VATS or SABR at Leeds Teaching 
Hospitals Trust over a period of 12 months. Patient eligibil-
ity for the study was assessed using the criteria listed in 
Table 1.
Patient‑reported outcomes questionnaires
Patients were invited to self-report patient-reported out-
comes (PROs) using online secure access via QTool soft-
ware at home or in clinic before the treatment and at follow-
up intervals. Appropriate training for the use of the QTool 
was offered to both clinicians and patients (Holch et al. 
2017). Paper administration was offered to patients with-
out internet access. Clinicians with access to the electronic 
patient medical record (EPR) were able to consult the PROs 
in real time during consultations. Patients were collecting 
Quality of Life data through the administration of the Euro-
pean Organization for Research and Treatment (EORTC) 
Quality of Life Questionnaire (QLQ C-30) and its Lung Can-
cer specific Module (LC-13) at baseline, and post-treatment 
Table 1  Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age 18 years and over Advanced disease (III–IV stages)
Diagnosis of NSCLC either from histology or multi-disciplinary team meeting 
(MDT/Tumour Board) with agreement on > 95% likelihood of diagnosis based 
on radiological evidence or both
Patient included in another quality of life study, which may 
increase patient burden and bias the answers of the question-
naires
Decision for either surgery or SABR
Able to give informed consent
Able to understand the language of the questionnaire
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at 6 weeks, 3, 6 and 12 months. At the baseline, they were 
also collecting decision self-efficacy data and at 6 weeks 
patient satisfaction through the PSQ-18.
The Patient Satisfaction Questionnaire Short Form (PSQ-
18) was chosen as it is a cross-cultural validated survey for 
use in different settings (Thayaparan and Mahdi 2013). It is 
short, reducing patient burden of filling in multiple ques-
tionnaires and covers the most important aspects of hospital 
attendance. The PSQ-18 questionnaire is an 18-item self-
administered survey including different scales reflecting the 
perceived level of satisfaction in relation to the care provided 
by doctors. The team behind this Likert scale questionnaire 
proposed seven dimensions of patient satisfaction directed 
toward their doctors. These are general satisfaction, techni-
cal quality, interpersonal manner, communication, financial 
aspects, time spent with doctor, and accessibility and con-
venience (Thayaparan and Mahdi 2013). Patient satisfac-
tion was only assessed at the first post-treatment time point 
(6 weeks). All items are scored (1–5) so that high scores 
reflect satisfaction with medical care. This was done to max-
imize response rate, as suggested by Bredart et al. (2005). 
Moreover, assessing satisfaction close to hospital recovery 
could allow for a better distinction among elements of sat-
isfaction and higher response variability (Kane et al. 1997).
The Decision Self-Efficacy (DSE) scale is an 11-item 
questionnaire assessing the efficacy of decision-making 
with a 5-point response scale to generate a score between 
0 and 100, with 0 indicating very low decision self-efficacy 
and 100 indicating very high decision self-efficacy. This 
instrument was shown to be reliable and valid for use in this 
population (Pompili et al. 2020). We administered the DSE 
at the pre-treatment time point.
Analysis
We compared patient satisfaction measured using the PSQ-
18 questionnaire between the VATS and SABR groups. 
Descriptive data summarise the characteristics of patients, 
and questionnaire responses.
We also explored preoperative factors that may predict 
patient satisfaction. The following variables were initially 
used in the analysis: age, preoperative forced expiratory 
volume in 1 s (FEV1%), gender, decision self-efficacy scale 
score (DSE), Index of multiple deprivation decile (IMD), 
Eastern Cooperative Oncology Group (ECOG) Performance 
Status (PS) and Carlson comorbidity index (CCI). Although 
the VATS and SABR groups were highly heterogeneous, 
limited numbers in each group meant it was not possible 
to run separate multivariable regression analyses for each 
group. One multivariable regression analysis of all 134 
patients was carried out and adjusted for treatment type. 
Variables with a p value < 0.1 were used as independent 
predictors in generalised linear regression analysis.
Results
Recruitment
In total, 356 patients were eligible to participate in the 
study in a 12 months period, with 244 consenting to take 
part (60%). Of these, nineteen patients were excluded from 
the analysis: seven did not receive any treatments for onco-
logical reasons, and twelve were deemed ineligible prior to 
treatment due to their suitability for open operation. Of the 
remaining 225 patients, 44 did not complete the trial: 23 
died (13 in the SABR group and 10 in the VATS group); 
9 became ineligible and 12 (eight patients in the SABR 
group and four in the VATS group) actively withdrew. Of 
the 12 patients who actively withdrew, five felt they had 
too many other time commitments to continue participa-
tion and the remaining seven did not provide a reason. Of 
the 225 participants, 91 failed to complete a patient satis-
faction questionnaire at 6 weeks and thus were excluded 
from the analysis.
Patient baseline demographics and clinical 
characteristics
The clinical details and baseline (pre-treatment) demo-
graphics of the 225 patients who underwent VATS or 
SABR are presented in Table 2. The two groups differ 
considerably in their pre-treatment clinical features. There 
were no major differences in the available demographic 
data for the total patients treated in the same period.
Clinical outcomes analysis demonstrated that patients 
treated with SABR experienced a higher proportion of 
Grade 1–2 complications, as defined by the Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0 
(Trotti et al. 2003) resulting in a higher rate of complica-
tions overall (Table 2).
Patients’ satisfaction results
The patient satisfaction questionnaire, administered at 
6 weeks, was completed by 60 SABR (66.6%) and 74 
VATS patients (62.7%). We did not find any significant 
differences between the two groups in any of the PSQ-18 
questionnaire subscales. In all scales, patients reported 
a moderate level of satisfaction with the care provided 
(Table 3).
The comparison between known groups (IMD domains, 
age, PS, gender and complications) in terms of general 
satisfaction showed that patients living in more deprived 
areas (higher IMD scores) were more satisfied. Patients 
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experiencing minor and major complications were also 
more satisfied 6 weeks after treatment (Table 4). The con-
tinuous variables are categorized and split at the mean 
value.
Patient satisfaction model
The univariate analysis of patient satisfaction was carried 
out on 134 patients (60 SABR + 74 VATS) who completed 
Table 2  Patient demographic and clinical details according to treatment
Results are expressed as means and standard deviations for numeric variables and as counts and percentages for categoric variables
SABR stereotactic ablative radiotherapy, IQR interquartile range, BMI body mass index, PS Eastern Cooperative Oncology Group (ECOG) per-
formance score, FEV1 forced expiratory volume in 1 s, DCLO carbon monoxide lung diffusion capacity, CCI Charlson comorbidity index, CAD 
coronary artery disease, CVD cerebrovascular disease, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DSE Deci-
sion self-efficacy, EORTC QLQ C-30 GH Global Health score of the EORTC QLQ C-30 questionnaire: 1–100 score with higher score represent-
ing better quality of life, LC-13 Dyspnoea Dyspnoea score of the EORTC Lung Cancer 13 Module: 1–100 score with higher score representing 
worse degree of symptoms
SABR (n = 95)
Mean or count
Median IQR Surgery (n = 130)
Mean or count
Median IQR p value
Age 74.3 (9.2) 75 70 to 80 70.0 (8.8) 71 65–76 < 0.001
Sex: male (n, %) 37 (39%) 62 (48%) 0.21
BMI (kg/m2) 27.3 (5.4) 26.5 24.5 to 30.0 26.3 (5.3) 26.5 22.9–29.0
FEV1% 76.6 (26.3) 77 60 to 90 88.0 (22.4) 91 73–101 < 0.001
DLCO % 71.0 (22.1) 71 57 to 82 83.4 (21.1) 82 68–97 < 0.001
CCI 2.1 (1.3) 2 1 to 3 1.2 (1) 1 0–2 < 0.001
PS > 1 (n, %) 54 (57%) 21 (16%) < 0.001
CAD (n, %) 32 (34%) 9 (6.9%) < 0.001
CVD (n, %) 12 (13%) 4 (3.1%) 0.008
CKD (n, %) 7 (7.4%) 1 (0.8%) 0.011
Diabetes (n, %) 22 (23%) 10 (7.6%) 0.001
COPD (n, %) 44 (46%) 38 (29%) 0.009
All complications (n, %) 85 (89%) 95 (73%) 0.002
Minor complications (Grades 1–2) 64 (67%) 68 (53%) 0.028
Major complications (Grades 3–5) 21 (22%) 27 (21%) 0.81
Treatment related deaths within 90 days (n, 
%)
3 (3%) 7 (5%) 0.52
Baseline QLQ-C-30 Global health (Mean 
(SD), (n completers))
53.8 (23.6), (n = 74) 71.2 (16.7), (n = 70) < 0.001
LC-13 Dyspnoea (Mean (SD), (n com-
pleters))
36.9 (26.9), (n = 69) 20.8 (22.1), (n = 63) < 0.001
DSE total score (mean (SD), (n completers)) 79.5 (23.1), (n = 73) 83.6 (22.9), (n = 85) 0.09
Table 3  Patient satisfaction 
results according to the 
treatment
The continuous variables are categorized and split at the mean value
a All items are scored (1–5) so that high scores reflect satisfaction with medical care
SABR stereotactic ablative radiotherapy, SD standard deviation
PSQ-18  SUBSCALESa SABR (n = 60) Surgery (n = 74) p value
General satisfaction (mean, SD) 3.82 (1) 3.89 (1) 0.6
Technical quality 3.88 (0.8) 3.95 (0.6) 0.81
Interpersonal manner 4.05 (0.99) 4.37 (0.6) 0.11
Communication 3.95 (0.93) 3.96 (0.81) 0.7
Financial aspects 4 (0.98) 4.08 (0.92) 0.7
Time spent with doctor 3.78 (0.9) 3.85 (0.9) 0.55
Accessibility and convenience 3.44 (0.7) 3.47 (0.8) 0.62
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the PSQ-18. Results of the regression are shown in Table 5. 
Multivariable regression analysis showed that the only pre-
treatment factors that remained independently associated 
with patient satisfaction were decision-making self-efficacy 
and age.
Discussion
Patient satisfaction results showed no difference between the 
two treatments for early-stage NSCLC. However, patients 
who experienced minor or major complications reported 
higher scores of patient satisfaction. We also demonstrated 
in our cohort that patients living in the more deprived areas 
reported higher satisfaction with care, although this asso-
ciation was no longer present in the regression analysis. 
Further, patients who felt more able to be involved in their 
treatment decision-making and patients who were older were 
more satisfied with care.
That patient satisfaction measure offers health services 
something different to clinical indicators, so is useful in 
helping services to identify ways to improve patient care. 
The fact that no association was detected between clinical 
indicators and patient satisfaction probably does not reflect 
the effect of the disease and treatment but rather provides 
information about the service.
Our results are discordant to the work by Barlesi et al. 
who found that the absence of postoperative complications 
in similar thoracic surgery patients, was the only quality 
index that showed weak but significant positive correlation 
with an index rating the satisfaction with the structure (Bar-
lesi et al. 2005).
Furthermore, results from this study regarding patient 
satisfaction and post-treatment morbidity also differ from 
those we have previously found in lung resection patients 
(Pompili et al. 2015) and in other studies using the Euro-
pean Organisation for Research and Treatment of Cancer 
(EORTC) IN-PATSAT32 (Bredart et al. 2005). The EORTC 
In-PATSAT32 is a multi-dimensional questionnaire, adapted 
to measure patient satisfaction related to physician and hos-
pital staff, as well as aspects of organisation of care and 
services (Bredart et al. 2005). It demonstrates reliability 
having been used in previous research (Pompili et al. 2013). 
It could be argued that some of the dissatisfaction caused 
by adverse events after surgery may not be alleviated by 
clear communication or the intensive care that complicated 
patients require. However, in this previous study, we used a 
different questionnaire which was administered at discharge. 
These factors may have influenced these divergent results. 
The two groups included in the current analysis were heter-
ogenous and the SABR population are day-cases and were, 
therefore, unable to rate satisfaction with the system and 
staff to the same extent that patients would be able to during 
an inpatient journey.
More recently, a US study found that patient satisfac-
tion scores amongst patients undergoing surgery for lung 
cancer were not significantly affected by postoperative 
complications. Satisfaction in the areas of communication 
Table 4  General patient satisfaction scores difference in known groups
Results are expressed as mean (SD)
*Statistical significance
a IMD: Index of multiple deprivation score 1–10. For all domains of the IMD, a greater score corresponds to greater deprivation
b Eastern Cooperative Oncology Group (ECOG) Performance Score
Group IMDa > 4.6 (most deprived) IMD < 4.6 (least deprived) p value
4.02 (0.9) 3.66 (1) 0.02*
Group Age > 72 Age < 72 p value
3.8 (1) 3.89 (0.9) 0.85
Group PSb > 1 PS < 1 p value
3.7 (1) 3.9 (0.9) 0.24
Group Major complications No major complications p value
4.06 (0.97) 3.72 (1) 0.04*
Group Minor complications No minor complications p value
4.06 (0.99) 3.72 (1) 0.03*
Group Female Male p value
3.83 (1) 3.88 (1) 0.64
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with doctors and nurses, however, decreased significantly 
with increasing length of stay suggesting an important role 
on enhancing provider communication skills (Singer et al. 
2019).
However, it is not easy to put these results in the context 
of studies exploring possible correlation between socio-eco-
nomic level and patient satisfaction. Comparability across 
studies is hampered by heterogeneous reporting and dif-
ferences in participant demographics. Systematic reviews 
show that socio-economic factors influence the use of health 
care services and subsequent survival rates in lung cancer 
patients (Forrest et al. 2013; Finke et al. 2018). In previ-
ous reports from our centre, there did not appear to be a 
significant relationship between socio-economic status and 
stage, performance status or outcome from lung cancer 
(Cheyne et al. 2013). Results from the UK National Can-
cer Patient Experience Survey (2012) showed that the sig-
nificant differences that exist among IMD and satisfaction 
of care are not unidimensional (Department of Health and 
Social Care 2012). However, there was a certain degree of 
consistency in the kind of questions that were less highly 
ranked by patients in the most deprived areas as identified 
by the IMD quintile, with most of the items relating to the 
providing and understanding of information. There may be 
some other factor in our population which resulted in the 
most socio-economically deprived patients being more satis-
fied with care. On the other hand, the more affluent patients 
have lower satisfaction, as they may have higher expecta-
tions and demands, having more access to external resources 
or private healthcare, which eventually may be translated 
into more information and confidence in seeking good care. 
Future analysis comparing our results with more up-to-date 
data from the 2017 National Cancer Patient Experience Sur-
vey may help to explore these differences and help commis-
sioners to reduce inequalities.
In our study group, there was a positive association 
between preoperative DSE scores and post-treatment sat-
isfaction, supporting our initial hypothesis. These results 
Table 5  Generalised linear regression of patient satisfaction by preoperative factors (N = 134)
SD standard deviation, CI confidence interval, VATS video-assisted thoracoscopic surgery, SABR stereotactic ablative radiotherapy, DSE decision 
self-efficacy, FEV1 forced expiratory volume in 1 s, CCI Charlson comorbidity index
* Statistical significance at < 0.01









No. or mean % or SD
Gender
 Female 76 56.7 0 0
 Male 58 43.3 − 0.02 − 0.19 to 0.15 0.80 − 0.05 − 0.22 to 0.12 0.53
Age (years)
 ≤ 65 25 18.7 − 0.62 − 0.64 to 0.02 0.003* − 0.47 − 0.89 to − 0.05 0.03*
 65–75 58 43.3 0 − 1.03 to − 0.21 0
 75+ 51 38.1 − 0.31 − 0.64 to 0.02 0.07 − 0.21 − 0.56 to 0.13 0.22
Treatment
 VATS 74 55.2 0 0
 SABR 60 44.8 − 0.03 − 0.20 to 0.14 0.71 0.001 − 0.17 to 0.17 0.99
DSE
 High > 90 62 46.3 0 0
 Low < 90 52 38.8 − 0.44 0.70 to − 0.18 0.001* − 0.38 − 0.64 to − 0.11 0.005*
 Not known 20 14.9 − 0.15 − 0.42 to 0.20 0.41 − 0.14 − 0.49 to 0.21 0.43
Index of multiple deprivation
 3, 4 or 5 (most 
deprived)
73 54.5 0 0
 1 or 2 (least 
deprived)
61 45.5 − 0.18 − 0.34 to − 0.01 0.04 − 0.10 − 0.27 to 0.07 0.25
FEV1 1.9 0.70 0.62
CCI 1.5 1.15 0.56
ECOG performance
 ≤ 1 88 65.7
 > 1 38 28.4 0.25
 Not known 8 6.0 0.50
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may be affected by the 6-week time interval selected for 
data collection. Participant attrition was greater at this point, 
especially in the VATS group, but the decision was made 
to assess satisfaction closer to hospital recovery to allow 
for a better distinction among elements of satisfaction and 
response variability (Kane et al. 1997).
Patients living in least deprived areas reported lower 
patient satisfaction and may in fact be DSE driven. The 
deprived group has a higher proportion of those with high 
DSE (61%) compared to the affluent group (46%).
Our data suggest that patients reported lower patient sat-
isfaction if they also have low DSE whether they are in the 
affluent or the deprived group. The difference in DSE may be 
more conflict from the researched, informed affluent group 
(borderline sig p = 0.1) and could suggest that the associa-
tion between IMD and satisfaction is no longer significant in 
the multivariable model because the association with DSE 
is stronger.
Decision self-efficacy is not a measure of quality of the 
decision-making process, but rather measures the involve-
ment of the patient in key decisions relating to treatment. But 
it has highlighted for the first time, the importance of patient 
attitudes surrounding treatment choices. Understanding the 
role of post-treatment patient satisfaction and its association 
with decision-making factors may provide important infor-
mation for clinical practice and future research.
Limitations
This cohort study was designed to explore factors associated 
with satisfaction and illustrate that patient satisfaction meas-
ures have an independent part to play in informing service 
quality apart from indicators of clinical and treatment effec-
tiveness. However, it was not a randomised control trial of an 
intervention designed to improve care, so although we can 
say decision self-efficacy and patient satisfaction are associ-
ated, we cannot say why. Prior evidence would suggest that 
interventions designed to enhance patient involvement in 
care are likely to increase decision self-efficacy and patient 
satisfaction with care, for example those involving patient 
decision aid interventions (Stacey et al. 2017). Although 
patient-reported measures are essential in understanding 
patient perspective in care, there are several limitations such 
as low response rates of questionnaires. In additional, patient 
satisfaction measures may be subject to social desirability 
bias in reporting, especially if care is continuing in a ser-
vice before treatment is completed. Furthermore, the PSQ-
18 questionnaire has been designed to assess generic satis-
faction and is not specific to either inpatient or outpatient 
care. This questionnaire was chosen instead of the EORTC 
PATSAT32, as SABR is an outpatient treatment. We cannot 
rule out the possibility that this questionnaire may not be 
capturing the same domains in these two different groups.
Conclusions
Patient satisfaction measures are important in service 
improvement as independent of the patient perception of 
the health problem and burden of symptoms and impact of 
treatment. It seems likely that supporting patient involve-
ment in treatment decision-making is associated with sat-
isfaction, independent of the treatment type. Socio-demo-
graphic factors did not affect reported satisfaction but may 
have influenced the efficacy in making the decision about 
treatment for early-stage NSCLC. The understanding of 
the clinical decision-process from patients deserves more 
investigation to improve patient-reported satisfaction with 
care for early-stage NSCLC.
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